Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2004-06-30
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose)
* on insulin secretion and
* insulin sensitivity in 12 healthy male subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
NCT00551564
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00044460
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
NCT00329225
Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.
NCT00154011
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
NCT01574820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rosiglitazone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PIERRE PETIT, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Centre d'Investigation Clinique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'Investigation Clinique
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Farret A, Chevassus H, Roux B, Petit P, Galtier F. Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study. Diabetologia. 2007 Jul;50(7):1384-7. doi: 10.1007/s00125-007-0682-4. Epub 2007 May 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7715
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.